Literature DB >> 28950347

The past and future of 'reported outcomes' in studies on chemotherapy neuropathy.

A S Beutler1, N Majithia2, C L Loprinzi3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28950347      PMCID： PMC5834098          DOI： 10.1093/annonc/mdx520

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

Authors:  R J Stephens; P Hopwood; D J Girling; D Machin
Journal:  Qual Life Res       Date:  1997-04       Impact factor: 4.147

2.  Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Authors:  Jennifer Le-Rademacher; Rahul Kanwar; Drew Seisler; Deirdre R Pachman; Rui Qin; Alexej Abyzov; Kathryn J Ruddy; Michaela S Banck; Ellen M Lavoie Smith; Susan G Dorsey; Neil K Aaronson; Jeff Sloan; Charles L Loprinzi; Andreas S Beutler
Journal:  Support Care Cancer       Date:  2017-06-20       Impact factor: 3.603

3.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

Authors:  Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag
Journal:  JAMA       Date:  2017-07-11       Impact factor: 56.272

4.  Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.

Authors:  Steven M Grunberg; Robert R Deuson; Panagiotis Mavros; Olga Geling; Mogens Hansen; Giorgio Cruciani; Bruno Daniele; Gerard De Pouvourville; Edward B Rubenstein; Gedske Daugaard
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

5.  Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.

Authors:  Andreas S Beutler; Amit A Kulkarni; Rahul Kanwar; Christopher J Klein; Terry M Therneau; Rui Qin; Michaela S Banck; Ganesh K Boora; Kathryn J Ruddy; Yanhong Wu; Regenia L Smalley; Julie M Cunningham; Nguyet Anh Le-Lindqwister; Peter Beyerlein; Gary P Schroth; Anthony J Windebank; Stephan Züchner; Charles L Loprinzi
Journal:  Ann Neurol       Date:  2014-09-17       Impact factor: 10.422

6.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

7.  Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

Authors:  Kojiro Shimozuma; Yasuo Ohashi; Ayano Takeuchi; Toshihiko Aranishi; Satoshi Morita; Katsumasa Kuroi; Shozo Ohsumi; Haruhiko Makino; Hirohumi Mukai; Noriyuki Katsumata; Yoshihide Sunada; Toru Watanabe; Frederick H Hausheer
Journal:  Support Care Cancer       Date:  2009-03-28       Impact factor: 3.603

8.  Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.

Authors:  D J Mahood; A M Dose; C L Loprinzi; M H Veeder; L M Athmann; T M Therneau; J M Sorensen; D K Gainey; J A Mailliard; N L Gusa
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

9.  Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.

Authors:  S B Park; J B Kwok; R Asher; C K Lee; P Beale; F Selle; M Friedlander
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976
  9 in total
  4 in total

1.  Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Authors:  Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry
Journal:  Clin Cancer Res       Date:  2018-04-27       Impact factor: 12.531

2.  Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.

Authors:  Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

3.  Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.

Authors:  Nicolas Kerckhove; Jérome Busserolles; Trevor Stanbury; Bruno Pereira; Valérie Plence; Franck Bonnetain; Ivan Krakowski; Alain Eschalier; Denis Pezet; David Balayssac
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

4.  Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.

Authors:  Nicolas Kerckhove; David Tougeron; Côme Lepage; Denis Pezet; Karine Le Malicot; Manon Pelkowski; Bruno Pereira; David Balayssac
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.